{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:29:03Z","timestamp":1790666943121,"version":"4.1.0"},"reference-count":121,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The majority of historical therapies for managing T-cell lymphomas (TCLs) have consisted of T-cell\u2013depleting strategies. Unfortunately, these forms of therapies can hamper the ability to mount effective antitumor immune responses. Recently, the use of checkpoint inhibitors has revolutionized the therapy of solid and hematologic malignancies. The development of immunotherapies for the management of TCL has lagged behind other malignancies given 2 central reasons: (1) the competing balance of depleting malignant T cells while simultaneously enhancing an antitumor T-cell response and (2) concern for tumor hyperprogression by blocking inhibitory signals on the surface of the malignant T cell, thereby leading to further proliferation of the malignant cells. These challenges were highlighted with the discovery that programmed cell death protein 1 (PD-1) functions paradoxically as a haploinsufficient tumor suppressor in preclinical TCL models. In contrast, some preclinical and clinical evidence suggests that PD-1\/programmed death ligand 1 may become an important therapeutic tool in the management of patients with TCL. Improved understanding of the immune landscape of TCL is necessary in order to identify subsets of patients most likely to benefit from checkpoint-inhibitor therapy. With increased preclinical research focus on the tumor microenvironment, substantial strides are being made in understanding how to harness the power of the immune system to treat TCLs. In this review, designed to be a \u201ccall to action,\u201d we discuss the challenges and opportunities of using immune-modulating therapies, with a focus on checkpoint inhibitors, for the treatment of patients with TCL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001966","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T15:38:56Z","timestamp":1599579536000},"page":"4256-4266","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas"],"prefix":"10.1182","volume":"4","author":[{"given":"Alexander","family":"Neuwelt","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Richmond Veterans Affairs Medical Center, Richmond, VA;"},{"name":"Division of Hematology and Oncology, Virginia Commonwealth University, Richmond, VA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Al-Juhaishi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Richmond Veterans Affairs Medical Center, Richmond, VA;"},{"name":"Division of Hematology and Oncology, Virginia Commonwealth University, Richmond, VA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9738-4167","authenticated-orcid":false,"given":"Eduardo","family":"Davila","sequence":"additional","affiliation":[{"name":"Division of Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3872-0615","authenticated-orcid":false,"given":"Bradley","family":"Haverkos","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Colorado, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,9,8]]},"reference":[{"issue":"20","key":"2020090811382678400_B1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2020090811382678400_B2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11899-016-0353-y","article-title":"T-cell lymphoma epidemiology: the known and unknown","volume":"11","author":"Phan","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"2020090811382678400_B3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.6004\/jnccn.2018.0007","article-title":"NCCN guidelines insights: T-cell lymphomas, version 2.2018","volume":"16","author":"Horwitz","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"16","key":"2020090811382678400_B4","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2020090811382678400_B5","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1016\/S2352-3026(18)30047-4","article-title":"Optimising initial treatment for peripheral T-cell lymphoma: a tough nut to CHOP","volume":"5","author":"Wilcox","year":"2018","journal-title":"Lancet Haematol"},{"issue":"18","key":"2020090811382678400_B6","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2020090811382678400_B7","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2020090811382678400_B8","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3324\/haematol.2017.167742","article-title":"Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707","volume":"102","author":"Maeda","year":"2017","journal-title":"Haematologica"},{"issue":"10168","key":"2020090811382678400_B9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"2020090811382678400_B10","unstructured":"National Comprehensive Cancer Network (NCCN) . Primary Cutaneous Lymphomas.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/primary_cutaneous.pdf. Accessed 10 April 2020."},{"issue":"2","key":"2020090811382678400_B11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/17474086.2017.1270201","article-title":"Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?","volume":"10","author":"Virmani","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"2020090811382678400_B12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40257-016-0177-5","article-title":"Cutaneous T-cell lymphoma: a review with a focus on targeted agents","volume":"17","author":"Devata","year":"2016","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"2020090811382678400_B13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"2020090811382678400_B14","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res"},{"issue":"8","key":"2020090811382678400_B15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2020090811382678400_B16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-3-319-99716-2_3","article-title":"Tumor microenvironment in T-cell lymphomas","volume":"176","author":"Bennani","year":"2019","journal-title":"Cancer Treat Res"},{"key":"2020090811382678400_B17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.semcancer.2013.11.004","article-title":"The microenvironment in T-cell lymphomas: emerging themes","volume":"24","author":"Gaulard","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"19","key":"2020090811382678400_B18","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2020090811382678400_B19","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S1074-7613(01)00252-7","article-title":"CD8 binding to MHC class I molecules is influenced by T cell maturation and glycosylation","volume":"15","author":"Daniels","year":"2001","journal-title":"Immunity"},{"issue":"2","key":"2020090811382678400_B20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.it.2014.12.001","article-title":"Confusing signals: recent progress in CTLA-4 biology","volume":"36","author":"Walker","year":"2015","journal-title":"Trends Immunol"},{"issue":"3","key":"2020090811382678400_B21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/35105024","article-title":"T-cell regulation by CD28 and CTLA-4","volume":"1","author":"Alegre","year":"2001","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2020090811382678400_B22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/CCO.0000000000000243","article-title":"Tumor microenvironment in mycosis fungoides and S\u00e9zary syndrome","volume":"28","author":"Rubio Gonzalez","year":"2016","journal-title":"Curr Opin Oncol"},{"issue":"10","key":"2020090811382678400_B23","first-page":"21","article-title":"Immunophenotypic diagnosis of primary cutaneous lymphomas: a review for the practicing dermatologist","volume":"3","author":"Campbell","year":"2010","journal-title":"J Clin Aesthet Dermatol"},{"issue":"8","key":"2020090811382678400_B24","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1182\/blood.V99.8.2929","article-title":"The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells","volume":"99","author":"Berger","year":"2002","journal-title":"Blood"},{"issue":"8","key":"2020090811382678400_B25","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/2326-6066.CIR-17-0270","article-title":"Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile","volume":"6","author":"Querfeld","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"2020090811382678400_B26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.semcancer.2012.02.002","article-title":"Differentiation and gene expression profile of tumor-associated macrophages","volume":"22","author":"Schmieder","year":"2012","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2020090811382678400_B27","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/10428194.2010.529204","article-title":"Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified","volume":"52","author":"Zhang","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2020090811382678400_B28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jdermsci.2012.07.007","article-title":"Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma","volume":"68","author":"Sugaya","year":"2012","journal-title":"J Dermatol Sci"},{"key":"2020090811382678400_B29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/978-1-60327-360-2_13","article-title":"Liposomes for specific depletion of macrophages from organs and tissues","volume":"605","author":"van Rooijen","year":"2010","journal-title":"Methods Mol Biol"},{"issue":"11","key":"2020090811382678400_B30","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1038\/jid.2014.206","article-title":"Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo","volume":"134","author":"Wu","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2020090811382678400_B31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/exd.12894","article-title":"Mac attack: macrophages as key drivers of cutaneous T-cell lymphoma pathogenesis","volume":"25","author":"Assaf","year":"2016","journal-title":"Exp Dermatol"},{"issue":"32","key":"2020090811382678400_B32","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020090811382678400_B33","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1200\/JCO.2013.50.9471","article-title":"Targeting tumor-infiltrating B cells in cutaneous T-cell lymphoma","volume":"34","author":"Theurich","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020090811382678400_B34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8274.CD-10-0028","article-title":"Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy","volume":"1","author":"DeNardo","year":"2011","journal-title":"Cancer Discov"},{"issue":"6","key":"2020090811382678400_B35","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1186\/bcr3072","article-title":"Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer","volume":"13","author":"West","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"5","key":"2020090811382678400_B36","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2020090811382678400_B37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance","volume":"39","author":"Zitvogel","year":"2013","journal-title":"Immunity"},{"key":"2020090811382678400_B38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"2020090811382678400_B39","first-page":"187","article-title":"Combinatorial strategies for the induction of immunogenic cell death","volume":"6","author":"Bezu","year":"2015","journal-title":"Front Immunol"},{"issue":"14","key":"2020090811382678400_B40","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1158\/0008-5472.CAN-11-0950","article-title":"Human tumor cells killed by anthracyclines induce a tumor-specific immune response","volume":"71","author":"Fucikova","year":"2011","journal-title":"Cancer Res"},{"issue":"22","key":"2020090811382678400_B41","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1158\/0008-5472.CAN-10-1825","article-title":"Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death","volume":"70","author":"Zappasodi","year":"2010","journal-title":"Cancer Res"},{"issue":"3","key":"2020090811382678400_B42","doi-asserted-by":"crossref","first-page":"e32542","DOI":"10.1371\/journal.pone.0032542","article-title":"Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells","volume":"7","author":"Wan","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"2020090811382678400_B43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"4","key":"2020090811382678400_B44","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"issue":"6","key":"2020090811382678400_B45","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"issue":"2","key":"2020090811382678400_B46","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/PAS.0b013e3181cc7e79","article-title":"PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis","volume":"34","author":"Krishnan","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"2020090811382678400_B47","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2009-04-216671","article-title":"B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2020090811382678400_B48","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1080\/10428194.2019.1602266","article-title":"The prognostic value of toll-like receptor5 and programmed cell death-ligand1 in patients with peripheral T-cell non-Hodgkin lymphoma","volume":"60","author":"Sun","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2020090811382678400_B49","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/DAD.0b013e31821c35cb","article-title":"Expression patterns of the immunosuppressive proteins PD-1\/CD279 and PD-L1\/CD274 at different stages of cutaneous T-cell lymphoma\/mycosis fungoides","volume":"34","author":"Kantekure","year":"2012","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"2020090811382678400_B50","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/bloodadvances.2018025114","article-title":"Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR","volume":"3","author":"Murray","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2020090811382678400_B51","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncologist"},{"issue":"7463","key":"2020090811382678400_B52","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer [published correction appears in Nature. 2013;502(7470):258]","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"15","key":"2020090811382678400_B53","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"issue":"7484","key":"2020090811382678400_B54","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"issue":"12","key":"2020090811382678400_B55","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","volume":"33","author":"Watatani","year":"2019","journal-title":"Leukemia"},{"issue":"14","key":"2020090811382678400_B56","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"2020090811382678400_B57","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"2020090811382678400_B58","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"issue":"12","key":"2020090811382678400_B59","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and S\u00e9zary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"issue":"12","key":"2020090811382678400_B60","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of S\u00e9zary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet"},{"issue":"26","key":"2020090811382678400_B61","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/blood-2016-02-699843","article-title":"Candidate driver genes involved in genome maintenance and DNA repair in S\u00e9zary syndrome","volume":"127","author":"Woollard","year":"2016","journal-title":"Blood"},{"issue":"7683","key":"2020090811382678400_B62","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature24649","article-title":"PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis [published correction appears in Nature. 2018;553(7687):238]","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature"},{"issue":"2","key":"2020090811382678400_B63","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2404045","article-title":"Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma","volume":"20","author":"Streubel","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"2020090811382678400_B64","doi-asserted-by":"crossref","first-page":"e000104","DOI":"10.1136\/jitc-2019-000104","article-title":"T-cell lymphoma secondary to checkpoint inhibitor therapy","volume":"8","author":"Anand","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"20","key":"2020090811382678400_B65","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"2020090811382678400_B66","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2019002038","article-title":"Rapid progression of adult T-cell leukemia\/lymphoma as tumor-infiltrating Tregs after PD-1 blockade","volume":"134","author":"Rauch","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2020090811382678400_B67","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMc1807852","article-title":"PD-1 inhibitor therapy in adult T-cell leukemia\u2013lymphoma","volume":"379","author":"Ishitsuka","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"2020090811382678400_B68","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020090811382678400_B69","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and Sezary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2020090811382678400_B70","article-title":"A phase II study of nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma [abstract]","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2020090811382678400_B71","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2020090811382678400_B72","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"17","key":"2020090811382678400_B73","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"2020090811382678400_B74","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3389\/fonc.2019.00127","article-title":"Opportunities to target the life cycle of Epstein-Barr virus (EBV) in EBV-associated lymphoproliferative disorders","volume":"9","author":"Dugan","year":"2019","journal-title":"Front Oncol"},{"issue":"22","key":"2020090811382678400_B75","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1158\/0008-5472.CAN-18-1342","article-title":"Genomic characterization of six virus-associated cancers identifies changes in the tumor immune microenvironment and altered genetic programs","volume":"78","author":"Varn","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"2020090811382678400_B76","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s42003-019-0352-3","article-title":"Dynamic host immune response in virus-associated cancers","volume":"2","author":"Cao","year":"2019","journal-title":"Commun Biol"},{"issue":"8","key":"2020090811382678400_B78","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"issue":"10","key":"2020090811382678400_B79","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1158\/2159-8290.CD-18-1259","article-title":"The mechanism of anti-PD-L1 antibody efficacy against PD-L1-negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector","volume":"9","author":"Dong","year":"2019","journal-title":"Cancer Discov"},{"issue":"2","key":"2020090811382678400_B80","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int Immunol"},{"issue":"3","key":"2020090811382678400_B81","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0006-291X(03)01257-9","article-title":"Differential binding properties of B7-H1 and B7-DC to programmed death-1","volume":"307","author":"Youngnak","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"2020090811382678400_B82","doi-asserted-by":"crossref","first-page":"656340","DOI":"10.1155\/2012\/656340","article-title":"Programmed death ligand 2 in cancer-induced immune suppression","volume":"2012","author":"Rozali","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"15","key":"2020090811382678400_B83","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1158\/1078-0432.CCR-18-3991","article-title":"Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity","volume":"25","author":"Tanegashima","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2020090811382678400_B84","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.jid.2017.03.025","article-title":"Increased soluble CD226 in sera of patients with cutaneous T-cell lymphoma mediates cytotoxic activity against tumor cells via CD155","volume":"137","author":"Takahashi","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2020090811382678400_B85","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jid.2016.08.016","article-title":"TIGIT and Helios are highly expressed on CD4+ T cells in S\u00e9zary syndrome patients","volume":"137","author":"Jariwala","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"9","key":"2020090811382678400_B86","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/cas.12986","article-title":"Lymphocyte-activation gene-3, an important immune checkpoint in cancer","volume":"107","author":"He","year":"2016","journal-title":"Cancer Sci"},{"issue":"9","key":"2020090811382678400_B87","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.4049\/jimmunol.1002050","article-title":"MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis","volume":"186","author":"Hemon","year":"2011","journal-title":"J Immunol"},{"issue":"8","key":"2020090811382678400_B88","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1080\/10428194.2018.1564827","article-title":"Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in S\u00e9zary syndrome","volume":"60","author":"Anzengruber","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2020090811382678400_B89","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3324\/haematol.2015.139253","article-title":"Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma","volume":"101","author":"Yoo","year":"2016","journal-title":"Haematologica"},{"issue":"6","key":"2020090811382678400_B90","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.3324\/haematol.2016.147074","article-title":"Comment on: frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al [comment]","volume":"101","author":"Gong","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"2020090811382678400_B91","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/leu.2015.357","article-title":"Recurrent activating mutations of CD28 in peripheral T-cell lymphomas","volume":"30","author":"Rohr","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"2020090811382678400_B92","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/sj.jid.5700029","article-title":"Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides \u2013 cutaneous T cell lymphoma","volume":"126","author":"Wong","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2020090811382678400_B93","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mgg3.121","article-title":"Personalized treatment of S\u00e9zary syndrome by targeting a novel CTLA4:CD28 fusion","volume":"3","author":"Sekulic","year":"2015","journal-title":"Mol Genet Genomic Med"},{"issue":"5","key":"2020090811382678400_B94","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"issue":"9","key":"2020090811382678400_B95","doi-asserted-by":"crossref","first-page":"e0137345","DOI":"10.1371\/journal.pone.0137345","article-title":"Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"issue":"18","key":"2020090811382678400_B96","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2020090811382678400_B97","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/CCO.0000000000000468","article-title":"Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience","volume":"30","author":"Folkes","year":"2018","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"2020090811382678400_B98","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/bloodadvances.2018030577","article-title":"Targeting CD47 in S\u00e9zary syndrome with SIRP\u03b1Fc","volume":"3","author":"Johnson","year":"2019","journal-title":"Blood Adv"},{"issue":"22","key":"2020090811382678400_B99","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"2020090811382678400_B100","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"key":"2020090811382678400_B101","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy","volume":"7","author":"Johnson","year":"2016","journal-title":"Nat Commun"},{"key":"2020090811382678400_B102","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.3389\/fimmu.2018.02144","article-title":"Epithelial MHC class II expression and its role in antigen presentation in the gastrointestinal and respiratory tracts","volume":"9","author":"Wosen","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"2020090811382678400_B103","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/1074-7613(95)90049-7","article-title":"Control of memory CD4 T cell activation: MHC class II molecules on APCs and CD4 ligation inhibit memory but not naive CD4 T cells","volume":"2","author":"Farber","year":"1995","journal-title":"Immunity"},{"issue":"6","key":"2020090811382678400_B104","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1365-2133.1994.tb08579.x","article-title":"In cutaneous T-cell lymphoma, class II MHC molecules on CD1+ antigen-presenting cells are upregulated in involved compared with uninvolved epidermis","volume":"131","author":"Hansen","year":"1994","journal-title":"Br J Dermatol"},{"issue":"2","key":"2020090811382678400_B105","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/imm.12136","article-title":"Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma","volume":"140","author":"Cycon","year":"2013","journal-title":"Immunology"},{"issue":"1","key":"2020090811382678400_B106","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/icb.2011.96","article-title":"Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer","volume":"90","author":"Woan","year":"2012","journal-title":"Immunol Cell Biol"},{"issue":"8","key":"2020090811382678400_B107","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/2326-6066.CIR-18-0875","article-title":"Histone deacetylase inhibition sensitizes PD1 blockade-resistant B-cell lymphomas","volume":"7","author":"Wang","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2020090811382678400_B108","doi-asserted-by":"crossref","first-page":"e000441","DOI":"10.1136\/jitc-2019-000441","article-title":"Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK\/ERK signaling and epigenetic mechanisms","volume":"8","author":"Neuwelt","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2020090811382678400_B109","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1038\/s41598-019-42237-3","article-title":"Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells [published correction appears in Sci Rep. 2019;9(1):14824]","volume":"9","author":"Knox","year":"2019","journal-title":"Sci Rep"},{"issue":"8","key":"2020090811382678400_B110","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2217\/epi-2016-0066","article-title":"HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?","volume":"8","author":"Beg","year":"2016","journal-title":"Epigenomics"},{"issue":"suppl 1","key":"2020090811382678400_B111","article-title":"A phase I\/II study to examine the safety and efficacy of pembrolizumab 200 mg fixed dose administered every 3 weeks (Q3W) in combination with romidepsin in relapsed or refractory peripheral T-cell lymphoma (PTCL) [abstract]","volume":"134","author":"Iyer","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2020090811382678400_B112","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41423-018-0026-y","article-title":"Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment [published correction appears in Cell Mol Immunol. 2020;17(1):111-112]","volume":"16","author":"Yu","year":"2019","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"2020090811382678400_B113","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"2020090811382678400_B114","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3389\/fphar.2018.01443","article-title":"Immunomodulatory properties of DNA hypomethylating agents: selecting the optimal epigenetic partner for cancer immunotherapy","volume":"9","author":"Fazio","year":"2018","journal-title":"Front Pharmacol"},{"issue":"21","key":"2020090811382678400_B115","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"issue":"17","key":"2020090811382678400_B116","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study","volume":"134","author":"O\u2019Connor","year":"2019","journal-title":"Blood"},{"key":"2020090811382678400_B117","doi-asserted-by":"crossref","unstructured":"Marchi E , MaH, MontanariF, et al The integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma. In: Proceedings from the American Association for Cancer Research (AACR) Virtual Annual Meeting I; 27-28 April 2020. Abstract CT160.","DOI":"10.1158\/1538-7445.AM2020-CT160"},{"issue":"8","key":"2020090811382678400_B118","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2020090811382678400_B119","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2020090811382678400_B120","article-title":"Safety and anti-tumor activity of CD5 CAR T cells in patients with relapsed\/refractory T-cell malignancies [abstract]","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2020090811382678400_B121","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MOH.0000000000000548","article-title":"Mechanisms of failure of chimeric antigen receptor T-cell therapy","volume":"26","author":"Li","year":"2019","journal-title":"Curr Opin Hematol"},{"issue":"6","key":"2020090811382678400_B122","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41409-019-0657-3","article-title":"Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma","volume":"55","author":"Hill","year":"2020","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/17\/4256\/1757366\/advancesadv2020001966.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/17\/4256\/1757366\/advancesadv2020001966.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T10:46:40Z","timestamp":1668682000000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/17\/4256\/463645\/Enhancing-antitumor-immunity-through-checkpoint"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":121,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2020,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001966","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,8]]}}}